1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nexalis Therapeutics Limited

Nexalis Therapeutics Limited

NX1.AX
Nexalis Therapeutics LimitedAU flagAustralian Securities Exchange
0.02
AUD
- -
- -
3.80MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.03
-0.02
-0.03
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.07
0.03
0.01
0.01
0.02
0.01
- -
- -
- -
Tangible Book Value per Share
- -
0.06
0.02
0.01
0.01
0.02
0.01
- -
- -
- -
Basic Weighted Avg Shares
27
78
78
80
100
169
174
191
215
216
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-561.04
-566.64
-4,264.58
-9,676.98
-672.98
-7,879.44
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-2
-2
-1
-1
-2
-1
-1
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-424.69
-542.2
-4,877.06
-8,054.01
-664.15
-7,647.6
- -
- -
- -
Working Capital
- -
4
2
- -
2
3
2
1
- -
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
5
3
- -
2
3
2
1
- -
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-81.24
-48.24
-148.65
-98.18
-51.72
-82.36
-111.3
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
319.85%
1,736.91%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
14.86%
33.85%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Darryl Davies
Sector
Healthcare
Industry
Biotechnology
Address
505 Little Collins Street Melbourne VIC Australia 3000
IPO Date
Jan 10, 2017
Website
inhalerx.com.au
Similar Companies
Oncodesign S.A. (ALONC.PA)
Kezar Life Sciences, Inc. (KZR)
Calliditas Therapeutics AB (publ) (CALTX.ST)
Keros Therapeutics, Inc. (KROS)
Biostax Corp. (BTAX)
Bone Biologics Corporation (BBLGW)
Business
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.